FDA approves Lenvatinib for the treatment of thyroid cancer

1. In early 2015, US Food and Drug Administration or FDA approved Generic Lenvatinib / Brand Lenvima for treating patients diagnosed with thyroid cancer. It can be prescribed for treating metastatic differentiated (locally recurrent) thyroid cancer that has grown even after treatment therapy (radioactive iodine). Metastatic thyroid cancer is the most commonly diagnosed form of thyroid cancer. Over 56,500 new cases of metastatic differentiated thyroid cancer are estimated annually. However, the 5-year survival rate for patients of this cancer is close to 98%. Lenvatinib / Lenvima cost information Lenvatinib Mechanism of Action Lenvatinib / Lenvima works by targeting the molecules that enable the growth of the tumour in several different ways.

2. Lenvatinib molecules target receptor families that have involvement in supporting growth of the tumours and its survival. This process is known as angiogenesis. Such receptor families involve fibroblast growth factor or FGF, endothelial growth factor or VGEF and platelet derived alpha growth receptor. Lenvatinib can also block other types of molecules that may enable the growth and further spread of the tumour such as RET or KIT. Lenvatinib / Lenvima Side Effects Some Lenvatinib side effects include: ✓Diarrhea or constipation ✓Nausea and/or vomiting ✓Kidney problems, signs: increase urination during the night, blood in urine or change in urine color ✓Tiredness, weakness and/or difficulty in sleeping ✓Hoarseness ✓Liver problems, signs: jaundice, dark urine & clay colored stools, loss of appetite and/or sudden weight loss ✓Rashes, redness and/or itchiness on the palm of the hands or sole of the feet ✓Dry mouth and increased thirst ✓Dizziness and/or light-headedness ✓Heart problems, signs: shortness of breath and/or swelling Some of the more common side effects include: ✓Vomiting, nausea and/or headache ✓Pain in joints and muscles ✓Sudden weight loss and/or loss of appetite ✓High blood pressure ✓Mouth sores Lenvatinib cost information The FDA approved Lenvatinib / Lenvima on the basis of the results from a clinical trial that is submitted to the New England Journal of Medicine. Treatment with Lenvatinib caused the progression-free survival duration to increase significantly from 3.6 months to 18.3 months.

3. Of the patients who received Lenvatinib, it was found that the tumour size was reduced in over 65% of the patients. Due to the role of angiogenesis in enablement of different solid tumour’s growth. Lenvatinib is being studied in other clinical trials focused on studying its effects on other types of cancers including ✓Liver cancer ✓Kidney cancer ✓Non-small cell lung cancer Lenvatinib / Lenvima are generally available in the following dosages: ✓Generic Lenvatinib 4 mg Capsules ✓Generic Lenvatinib 10 mg Capsules ✓Brand Lenvima (Eisai) 4 mg Capsules ✓Brand Lenvima (Eisai) 4 mg Capsules The information provided on the page is meant for the purpose of being helpful and educational. It should not be considered as medical advice. Lenvatinib, lenvima, lenvatinib side effects, lenvima side effects, lenvatinib mechanism of action, lenvima cost, lenvatinib cost, lenvima 4mg, lenvatinib capsules